Since compensatory mechanisms between DGAT1 and DGAT2 exist30, and simultaneous suppression of DGAT1/2 activity exerts synergy when compared with that of mono-inhibition (Fig. 3f), Xanthohumol likely has a higher potential for clinical use against COVID-19 than A922500 as DGAT2 are abundantly expressed in blood, liver, and adipose tissues. Here, DGAT2 is linked to COVID-19.